in

HIV Endgame : ‘Avengers’ HVTN702, Imbokodo and Mosaico?

Is there a Vaccine to Prevent human immunodeficiency virus (HIV)?

The global fight against the human immunodeficiency virus (HIV)There is currently no vaccine available that will prevent HIV infection.

How many Vaccines and What Do They Do? Why Do We Need a Vaccine to Prevent HIV?

Vaccines are products made from very small amounts of weak or dead germs that can cause diseases. They help your immune system fight infections more effectively.

When you get vaccinated, its trigger your immune response, helping your body fight off and remember the Virus & if the Virus ever invades again. And since vaccines are made of very small amounts of weak/dead germs, they wont cause you to get sick.

HIV was identified in 1983. it took 47 years to develop the polio vaccine!There is no licensed vaccine against AIDS in last 38 years. We are still looking for a vaccine is not at all surprising. 35 million people worldwide are now infected with HIV/AIDS pandemic. Million people have lost their lives of HIV/AIDs.

HIV vaccines entering into the final stages of testing across the globe, ‘optimistic moments.’

  • 3 vaccines currently being tested in efficacy trials-
  • 1-HVTN702
  • 2-Imbokodo
  • 3-Mosaico

HVTN702

The oldest ongoing known HIV vaccine trial, HVTN 702, is based on a prior vaccine candidate, RV144, that was effective, but not effective enough against HIV/AIDS pandemic.

The oldest ongoing known HIV vaccine trial, HVTN 702, is based on a prior vaccine candidate, RV144, that was effective, but not effective enough against HIV/AIDS pandemic. Vaccine lowered the rate of HIV infections by about 30 percent.The way forward for vaccine researchers, adapted RV144’s successes to create HVTN 702.

HVTN 702 lowered the rate of HIV infections by about 30 percent.HVTN 702, launched in South Africa in 2016, was the first vaccine trial approved after the failure of RV144.HVTN 702 clinical results are expected in late 2021.

2-Imbokodo

Unlike HVTN 702, Imbokodo uses “mosaic” immunogens, which are “vaccine components designed to induce immune responses against a wide variety of global HIV strains,” according to the National Institutes of Health.

Imbokodo combination of two experimental vaccines to prevent HIV-The study vaccines are called Ad26.Mos4. HIV(Ad26 vaccine) and Clade C gp140 (protein vaccine).

“It’s unbelievable fact but a bitter truth, women between the ages of 18 and 25 — the prevalence of infection is well over 50 percent,”

Imbokodo, the second trial, was began in five southern African nations in 2017 and completed enrollment of 2,600 women. In southern African nations, heterosexual women are at extremely high risk of HIV infection.

Imbokodo Vaccine Myth You Should Not Believe

The vaccines imbokodo is being tested in this study CANNOT cause HIV infection or AIDS. They are not made from live HIV, killed HIV, parts taken from HIV, or HIV-infected human cells. They are made from synthetic (man-made) copies of HIV pieces and therefore cannot cause HIV infection or AIDS.

  • These study vaccines are experimental.These vaccines are only used for research. They are not available to the public or available for sale.The Ad26 and protein vaccines used in Imbokodo are also being given to 235 people in two studies in the US, Kenya, and Rwanda called HVTN 117 and HVTN 118.

In studies conducted to date, there have been no serious health problems related to these vaccines. However, there is always the possibility of problems that have not been seen yet.

Mosaic Vaccine: is this HIV Breakthrough We’ve Been Waiting for?

An experimental HIV vaccine that targets more strains of the virus than any other developed so far will start a late-stage clinical trial.Mosaic Vaccine incorporates genetic material from HIV strains from around the world.
  • Small trials of the mosaic vaccine in people showed that it prompted an immune response, such as the production of antibodies, against HIV.
  • The phase III trial will test the vaccine in transgender individuals and in men who have sex with men across the Americas and Europe.

The latest Mosaic study will enrol 3,800 participants across 8 countries, including Argentina, Italy, Mexico, Poland and the United States. Half of the participants will get four vaccine injections over the course of a year, and the other half will receive a placebo.The Mosaic team hopes that their vaccine will help to protect at least 65% of the study participants. They expect to get results by 2023.

What is pre-exposure prophylaxis (PrEP)?

www.transformative.today

  • Pre-exposure prophylaxis (PrEP) is a course of HIV drugs taken by HIV-negative people to prevent infection.
  • Taking PrEP correctly will virtually eliminate your risk of getting HIV.
  • PrEP won’t protect you against other sexually transmitted infections (STIs) such as hepatitis C. Condoms are still the best protection from these STIs.
  • PrEP is not taken for life – it is only taken for short periods when a person may be at risk of HIV infection.   

PrEP is different from PEP (Post-exposure prophylaxis), which is an emergency treatment for HIV taken after possible exposure to the virus.

If I take PrEP, can I stop using condoms?

PrEP will protect you from HIV, but it doesn’t give you any protection against sexually transmitted infections (STIs). Using a condom is the best way to prevent other STIs.PrEP also doesn’t prevent pregnancy.

Who can take PrEP?

PrEP is for people who are HIV-negative and more at risk of HIV infection. PrEP can be used by men and women, both trans and cisgender.

Is PrEP effective for vaginal and anal sex?

Yes. PrEP can prevent HIV infection during both vaginal and anal sex, but there are different recommendations for how to take it depending on your gender and the sex you have.

What do you think?

Written by transformative

Transformative is single-handedly maneuvered and navigated under the expert hands of Dr. Supriya Himanshu, Consulting Editor, Transformative. Dr. Supriya, who has spent more than 15 years in media industry, working with media houses like TOI, HT, MediaTransAsia, The Statesman, TheHindu, Danika Jagran, both in print and online space, from Deputy Editor to being a Freelancer, is conceptualizing the content and cover, in sync with today’s need.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Loading…

0

Forget FOMO, be a certified #JOMO!

A New Double-mutant Strain of Covid-19 Detected in India